In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics (BCLI – Research Report), with a price target of $8.00. The company's shares closed last Tuesday at $3.28, close to its 52-week low of $2.75. According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.4% and a 21.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brooklyn ImmunoTherapeutics. Brainstorm Cell Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.
https://www.tipranks.com/news/blurbs/maxim-group-keeps-their-buy-rating-on-brainstorm-cell-therapeutics-bcli?utm_source=advfn.com&utm_medium=referral
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Brainstorm Cell Therapeu... Charts.